[177Lu]Lu-ABY-271

N/A

Report date: 2025/11/20 13:28:19

Base Information

Drug Name[177Lu]Lu-ABY-271
Drug Alias Name177Lu-ABY-271
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agent +[4] 
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAffibody Medical AB
China Registration ClassN/A

Develop Information

Active CompaniesAffibody Medical ABAffibody Ab
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A